Dirk J. Duncker - Publications

Elevated 5-oxoproline levels and adverse outcomes in heart failure: Association with renal cortical OPLAH loss in a multi-comorbidity model.

Journal: Redox biology

Published: July 13, 2026

Non-invasive and invasive diagnostic modalities for the assessment of coronary vasomotor dysfunction in ANOCA patients.

Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Published: March 02, 2026

PD-1/PD-L1 Signaling in Non-ICI Myocarditis.

Journal: JACC. Basic to translational science

Published: February 13, 2026

Sex and gender differences in coronary pathophysiology and ischaemic heart disease.

Journal: European heart journal

Published: January 22, 2026

Pathophysiology, prevention, and management of coronary microvascular obstruction.

Journal: European heart journal

Published: September 23, 2025

Microvascular Occlusion and Postrecanalization Hyperperfusion in a Swine Model of Acute Ischemic Stroke.

Journal: Journal of the American Heart Association

Published: September 06, 2025

Impairment of local metabolic coronary control involves perfusion-contraction matching not supply-demand imbalance.

Journal: Basic research in cardiology

Published: September 05, 2025

Proteome organ aging and cardiometabolic risk in a population at risk for heart failure.

Journal: Cardiovascular diabetology

Published: August 11, 2025

Colchicine Alleviates Non-Atherosclerotic Vascular Aging by Targeting Endothelial Dysfunction and Inflammatory Status.

Journal: Journal of inflammation research

Published: June 03, 2025

FoxO1-zDHHC4-CD36 S-Acylation Axis Drives Metabolic Dysfunction in Diabetes.

Journal: Circulation research

Published: May 13, 2025

Vascular (dys)function in the failing heart.

Journal: Nature reviews. Cardiology

Published: April 30, 2025

Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial.

Journal: European journal of heart failure

Published: April 12, 2025